Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C1702
http://purl.obolibrary.org/obo/NCIT_C1702
Preferred Name

Rituximab
Definitions
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
prefLabel
Rituximab
label
Rituximab
CHEBI_ID
CHEBI:64357
PDQ_Closed_Trial_Search_ID
42613
code
C1702
Has_Target
prefixIRI
NCIT:C1702
in_subset
Display_Name
Rituximab
Preferred_Name
Rituximab
FDA_UNII_Code
4F4X42SYQ6
Contributing_Source
CTRP
FDA
Maps_To
Rituximab
CAS_Registry
174722-31-7
NSC Number
687451
NCI_Drug_Dictionary_ID
42613
Legacy Concept Name
Rituximab
type
ALT_DEFINITION
A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody.
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
42613
Accepted_Therapeutic_Use_For
Diffuse Large B-cell, CD20-positive, Non-Hodgkins Lymphoma (NHL)
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
UMLS_CUI
C0393022
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display